- VANFLYTA[R] (quizartinib) is a FLT3 inhibitor MHLW-approved based on a survival benefit compared to salvage chemotherapy
in adult patients with relapsed/refractory FLT3-ITD AML
The QuANTUM-R study demonstrated that quizartinib resulted in a statistically significant improvement in overall survival compared to salvage chemotherapy
when patients were selected with the LeukoStrat CDx FLT3 Mutation Assay.
Based on the data from the ADMIRAL trial, treatment with gilteritinib monotherapy versus salvage chemotherapy
in adult patients with relapsed or refractory AML with an FLT3 mutation showed that the median Overall Survival for patients who received XOSPATA was 9.3 months compared to 5.6 months for patients who received salvage chemotherapy
Targeted Hodgkin's lymphoma therapy with the antibody-drug conjugate Brentuximab vedotin (Bv) has proven to be superior to conventional salvage chemotherapy
and clinical trials are being conducted to incorporate Bv into frontline therapy that substitutes Bv for alkylating agents to minimize secondary malignancies.
This trial is evaluating the impact that the addition of targeted internalized radiation via Actimab-A to the salvage chemotherapy
regimen CLAG-M will have on safety and tolerability, response rates, rates of BMT or bone marrow transplant, PFS or progression-free survival, and OS or overall survival.
Rituximab added to an intensified salvage chemotherapy
program followed by autologous stem cell transplantation improved the outcome in relapsed and refractory aggressive non-Hodgkin lymphoma.
and autologous stem cell transplantation for peripheral T-cell lymphoma: A subset analysis of the Canadian cancer trials group LY.12 randomized phase 3 study.
She was started on salvage chemotherapy
with high dose Cytarabine plus Mitoxantrone (high-dose AraC and Mitoxantrone protocol).
Among patients with cisplatin-resistant disease, Feldman and colleagues discuss the ongoing clinical trial of conventional-dose salvage chemotherapy
versus high-dose chemotherapy with stem cell support (NCT02375204) and the background literature supporting the need for this important trial.
Hagenbeeket al., "Autologous bone marrow transplantation as compared with salvage chemotherapy
in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma," New England Journal of Medicine, vol.
At this point, he was considered a candidate for high-dose therapy with stem cell transplant if induced into remission and, with this intention, had started salvage chemotherapy